Akèy › VIH › Kalifòni › San Francisco
Etid klinik pou VIH nan San Francisco, CA
15 etid pou VIH ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
Ap rekriteFaz 1Volontè an sante akeyi
- Bridge HIV CRS, San Francisco
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
Ap rekriteEtid obsèvasyon
- San Francisco General Hospital, San Francisco
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Ap rekriteFaz 3
- Optimus Medical Group, San Francisco
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Ap rekriteFaz 2
- University of California, San Francisco, San Francisco
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
Ap rekrite
- University of California, San Francisco, San Francisco
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Ap rekriteEtid obsèvasyon
- University of California, San Francisco, San Francisco
Menopausal HT for Women Living With HIV (HoT)
Ap rekriteFaz 4
- 801 University of California, San Francisco HIV/AIDS CRS, San Francisco
CAR-T Cells for HIV Infection
Ap rekriteFaz 1/2
- Zuckerberg San Francisco General, San Francisco
SCOPE Analytic Treatment Interruption Protocol
Ap rekrite
- University of California San Francisco, San Francisco
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Ap rekriteFaz 2
- San Francisco General Hospital, San Francisco
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
Ap rekriteFaz 1Volontè an sante akeyi
- Bridge HIV, San Francisco Department of Public Health, San Francisco
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
Ap rekriteEtid obsèvasyon
- University of California, San Francisco, San Francisco
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
Ap rekrite
- Zuckerberg San Francisco General Hospital, San Francisco
- University of California San Francisco, San Francisco
Imaging Immune Activation in HIV by PET-MR
Ap rekriteFaz 2
- University of California, San Francisco, San Francisco
Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention
Ap rekriteVolontè an sante akeyi
- San Francisco AIDS Foundation, San Francisco
Etid VIH nan lòt vil
- Washington, DC22 etid
- New York City, NY19 etid
- Houston, TX17 etid
- Miami, FL17 etid
- Baltimore, MD16 etid
- Atlanta, GA14 etid
- Chicago, IL14 etid
- Boston, MA11 etid
- Philadelphia, PA11 etid
- San Diego, CA10 etid
- Los Angeles, CA9 etid
- Seattle, WA8 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Kansè poumon23 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè ovè19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.